Skip to content
DNDi Logo
  • DNDi INTERNATIONAL
  • DNDi JAPAN
  • DNDi LATIN AMERICA
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Menu
  • ABOUT DNDi
    • ABOUT DNDi NORTH AMERICA
    • OUR TEAM
    • BOARD OF DIRECTORS
    • OUR PUBLICATIONS
    • FINANCIALS
    • JOBS
    • Close
  • DISEASES & PROJECTS
  • ADVOCACY
  • MEDIA CENTER
  • DONATE
  • CONTACT
    • Close
  • Home

Media Center

RSS SCIENTIFIC ARTICLES

  • Oxfendazole mediates macrofilaricidal efficacy against the filarial nematode Litomosoides sigmodontis in vivo and inhibits Onchocerca spec. motility in vitro
  • Clinical features and treatment outcomes of visceral leishmaniasis patients admitted to three centers in Oromia, Ethiopia
  • Antileishmanial aminopyrazoles: studies into mechanisms and stability of experimental drug resistance

RSS PRESS RELEASES

  • DNDi short film about new treatment for sleeping sickness awarded Grand Prix at inaugural WHO film festival
  • Up to 45,000 people living with Chagas disease in the US at risk of severe COVID-19 complications
  • Marking World Chagas Day for the first time to help give visibility to this neglected disease

RSS NEWS

  • Message on the passing of Marleen Boelaert from DNDi Executive Director Dr Bernard Pécoul
  • DNDi welcomes renewed commitment of GHIT Fund for Chagas disease research
  • Message on the passing of Martin Khor from DNDi Executive Director Dr Bernard Pécoul and GARDP Executive Director Dr Manica Balasegaram

RSS IN THE MEDIA

  • Research: “This epidemic will be a detonator”
  • Medicamentos: ¿bienes públicos?
  • Hver åttende person rammes av en «glemt» sykdom

RSS Scientific Articles

  • Oxfendazole mediates macrofilaricidal efficacy against the filarial nematode Litomosoides sigmodontis in vivo and inhibits Onchocerca spec. motility in vitro
  • Clinical features and treatment outcomes of visceral leishmaniasis patients admitted to three centers in Oromia, Ethiopia
  • Antileishmanial aminopyrazoles: studies into mechanisms and stability of experimental drug resistance
  • Hépatite C : le prix des médicaments compromet l’élimination mondiale de la maladie

About DNDi

Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected patients.

Subscribe

Sign up for the E-news newsletter! By subscribing, you agree that all info submitted will be processed according to our Privacy Policy. You can unsubscribe any time.

I want to receive

Connect

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
  • Events

DNDi Worldwide

  • DNDi regional offices
  • DNDi Japan のサイトへはこちらから.
  • DNDi Latin America website
  • DNDi North America website

Donate

Support research for neglected disease treatments by making a gift

Authorize.net Seal

Charity Status

GuideStar Gold Participantnewyork-ac-seal-vertical-black-web

Social Mission Ratio

DNDi's social mission ratio

  • PRIVACY POLICY
  • TERMS OF USE
  • ACCEPTABLE USE POLICY
  • COOKIE POLICY
  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License
We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser. Read Cookie Policy. Close